Nuclear Medicine Market
Global Nuclear Medicine Market Size to Reach $24.9 Billion by 2030
[London, United Kingdom] – [1st June 2023] – The global nuclear medicine market size is expected to reach USD 24.9 billion by 2030, according to a new report by Pharmanucleus. The market is projected to grow at a CAGR of 13.8% during the forecast period from 2023 to 2030.
The growth of the nuclear medicine market is being driven by a number of factors, including the increasing prevalence of chronic diseases, the rising demand for minimally invasive procedures, and the development of new radiopharmaceuticals.
Chronic diseases such as cancer, heart disease, and Alzheimer’s disease are major drivers of the nuclear medicine market. These diseases are often difficult to diagnose and treat, and nuclear medicine imaging can provide valuable information to help doctors make accurate diagnoses and develop effective treatment plans.
The demand for minimally invasive procedures is also driving the growth of the nuclear medicine market. Nuclear medicine procedures are often less invasive than traditional surgical procedures, which can lead to shorter recovery times and lower costs.
The development of new radiopharmaceuticals is also a major factor driving the growth of the nuclear medicine market. Radiopharmaceuticals are radioactive drugs that are used to diagnose and treat diseases. The development of new radiopharmaceuticals is expanding the range of applications for nuclear medicine and making it a more effective tool for treating a variety of diseases.
The global nuclear medicine market is segmented by type, application, and region. By type, the market is segmented into radiopharmaceuticals, equipment, and services. By application, the market is segmented into oncology, cardiology, neurology, and other applications. By region, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World.
North America is the largest market for nuclear medicine, followed by Europe and Asia Pacific. The large market share of North America is attributed to the presence of a large number of well-established players in the region. The market in Asia Pacific is expected to grow at a faster pace during the forecast period, due to the rising prevalence of chronic diseases and the increasing demand for minimally invasive procedures in the region.
For more information about the report and to request a sample copy, please visit
Contact Us:
John.M
Business Consultant
john.m@pharmanucleus.com
Support: +44 (0)20 8470 4967
https://www.pharmanucleus.com/
About Pharmanucleus
Pharma Nucleus is a market research company that provides clients access to custom, syndicated reports and consulting on one platform. As a company with rich knowledge in analysis and research across healthcare domains, such as pharma, medical device and biotechnology. Insights derived from Pharma Nucleus help life sciences and other healthcare organizations accelerate the launch, development, and dissemination of life-saving therapies, navigate significant attention with key opinion leaders, and help ensure equitable access to healthcare services.